125 related articles for article (PubMed ID: 12017193)
1. High density- and beta-lipoprotein screening for risk of coronary artery disease in the context of new findings on reverse cholesterol transport.
Levinson SS
Ann Clin Lab Sci; 2002; 32(2):123-36. PubMed ID: 12017193
[TBL] [Abstract][Full Text] [Related]
2. Optimized automated apolipoprotein A-I assays as markers for coronary artery disease.
Levinson SS; Hobbs GA
Arch Pathol Lab Med; 1997 Jul; 121(7):678-84. PubMed ID: 9240901
[TBL] [Abstract][Full Text] [Related]
3. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
4. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries].
Bukowska H
Ann Acad Med Stetin; 1998; 44():29-43. PubMed ID: 9857530
[TBL] [Abstract][Full Text] [Related]
5. Comparison of apolipoprotein B and non-high-density lipoprotein cholesterol for identifying coronary artery disease risk based on receiver operating curve analysis.
Levinson SS
Am J Clin Pathol; 2007 Mar; 127(3):449-55. PubMed ID: 17276939
[TBL] [Abstract][Full Text] [Related]
6. Relationship between bilirubin, apolipoprotein B, and coronary artery disease.
Levinson SS
Ann Clin Lab Sci; 1997; 27(3):185-92. PubMed ID: 9142370
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study.
März W; Scharnagl H; Winkler K; Tiran A; Nauck M; Boehm BO; Winkelmann BR
Circulation; 2004 Nov; 110(19):3068-74. PubMed ID: 15505088
[TBL] [Abstract][Full Text] [Related]
8. Lipid and inflammatory markers for the prediction of coronary artery disease: a multi-marker approach.
Bogavac-Stanojević N; Jelić-Ivanović Z; Spasojević-Kalimanovska V; Spasić S; Kalimanovska-Ostrić D
Clin Biochem; 2007 Sep; 40(13-14):1000-6. PubMed ID: 17632095
[TBL] [Abstract][Full Text] [Related]
9. [Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks].
Onat A; Ozhan H; Can G; Hergenç G; Karabulut A; Albayrak S
Anadolu Kardiyol Derg; 2007 Jun; 7(2):128-33. PubMed ID: 17513206
[TBL] [Abstract][Full Text] [Related]
10. Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis.
Nishtar S; Wierzbicki AS; Lumb PJ; Lambert-Hammill M; Turner CN; Crook MA; Mattu MA; Shahab S; Badar A; Ehsan A; Marber MS; Gill J
Curr Med Res Opin; 2004 Jan; 20(1):55-62. PubMed ID: 14741073
[TBL] [Abstract][Full Text] [Related]
11. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
12. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
13. High-density lipoprotein cholesterol in coronary artery disease patients: is it as low as expected?
Uzunlulu M; Oğuz A; Tigen K
Anadolu Kardiyol Derg; 2005 Dec; 5(4):268-70. PubMed ID: 16330390
[TBL] [Abstract][Full Text] [Related]
14. Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease.
Rasouli M; Kiasari AM
Clin Biochem; 2006 Oct; 39(10):971-7. PubMed ID: 16963013
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
16. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
17. Genetic variations of the apolipoprotein B gene in Turkish patients with coronary artery disease.
Duman BS; Türkoğlu C; Akpinar B; Güden M; Vertii A; Cağatay P; Günay D; Sevim Büyükdevrim A
Ann Hum Biol; 2005; 32(5):620-9. PubMed ID: 16316917
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease.
Solymoss BC; Bourassa MG; Lespérance J; Levesque S; Marcil M; Varga S; Campeau L
Coron Artery Dis; 2003 May; 14(3):207-12. PubMed ID: 12702923
[TBL] [Abstract][Full Text] [Related]
19. Relationship between plasma lipid concentrations and HDL subclasses.
Yang Y; Yan B; Fu M; Xu Y; Tian Y
Clin Chim Acta; 2005 Apr; 354(1-2):49-58. PubMed ID: 15748599
[TBL] [Abstract][Full Text] [Related]
20. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
